Avril Biopharma Inc
Avril Biopharma, Inc. is an emerging company founded by Dr. Eluemuno Blyden that uses the latest biotechnologies to design, test and manufacture protein-based medicines on demand. We address the need for rapid production of affordable vaccines, therapeutic antibodies and diagnostic products.
Our opportunities are in two arenas –Global Health and Personalized Medicine. We have brought together the latest AI, genomics and synthetic biotechnologies to offer every patient access to the powerful promise of gene therapy, as well as chronic and infectious disease treatments – at an affordable price. Our technologies and business model are disruptive and can efficiently serve both small-scale and large- scale needs.
We are a pre-clinical stage company focused on developing a broadly applicable technology platform for rapid, low-cost, scalable production of medical proteins using eggs. We have successfully made prototype candidates for rabies vaccine, influenza vaccine and human serum proteins using our technology. At present, our focus is on providing a unique option for rapid development and scaled-up production of countermeasures for SARS-CoV-2 and COVID-19 in ordinary hen eggs.
Our international team comprises decades of experience in the biopharmaceutical industry where we have a strong network of alliances capably of implementing the solutions we design.
Structural Genetics
Structural Genetics™ is our platform for bioinformatics encompassing genomic analysis through designing blueprints for recombinant products. Our bioinformatics algorithms give novel insight into genetic and structural variation allowing us to rationally design and engineer new vaccines, therapeutics and diagnostics. We apply Structural Genetics™ to turn genetic sequence data into actionable drug and vaccine design decisions for those responsible for public health. For example, we can analyse the strains of emerging viruses like Influenza, SARS-COV-2 and others so that better vaccines and more reliable tests can be made to fight the diseases they cause.
AdCEV/Egg— Recombinant bioproduction platform
Our manufacturing technology is based on a simply bioreactor that nature made —hen eggs. Using an adenovirus derived vector system, we can produce desired recombinant molecules in the tried and trusted fertilized egg. Our AdCEV/Egg platform is a scalable platform in which to develop your diagnostic reagents, vaccines, therapeutics of biosimilars products under GLP or GMP specifications.
Through our industry partnerships, we can offer services in all the steps of the translational pathway:
- GLP production for research products
- Pilot-scale GMP production in eggs
- Purification SOP development
- Protein stabilization and vaccine formulation